

MEDICALLY ILL HOSPITALIZED PATIENTS FOR COVID –19 THROMBOSIS EXTENDED PROPHYLAXIS WITH RIVAROXABAN THERAPY: THE MICHELLE TRIAL

Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro, Valéria Cristina Resende Aguiar, Alex C. Spyropoulos, Giuliano Giova Volpiani, Caroline Candida Carvalho de Oliveira, Marcone Lima Sobreira, MD, Edwaldo Edner Joviliano, Cesar Dusilek, Kengi Itinose, Rogério Aparecido Dedivitis, André Sementilli Cortina, Suzanna Maria Viana Sanches, Nara Franzin de Moraes, Paulo Fernando Guimarães Morando Marzocchi Tierno, André Luiz Malavasi Longo de Oliveira, Adriano Tachibana, Rodrigo Caruso Chate, Marcus Vinícius Barbosa Santos, Bruno Bezerra de Menezes Cavalcante, Ricardo Cesar Rocha Moreira, Chang Chiann, Alfonso Tafur, Renato D. Lopes

On Behalf of The Michelle Trial Investigators

ESC CONGRESS 2021
THE DIGITAL EXPERIENCE

DECLARATION OF INTEREST

FOR EDUARDO RAMACCIOTTI

RESEARCH SUPPORT/P.I.	BMS/PFE, BAYER, MCTI
EMPLOYEE	No relevant conflicts of interest to declare
CONSULTANT	No relevant conflicts of interest to declare
MAJOR STOCKHOLDER	No relevant conflicts of interest to declare
SPEAKERS BUREAU	BMS/PFE, ASPEN, BAYER, Daiichi-Sankyo, BIOMM
HONORARIA	No relevant conflicts of interest to declare
SCIENTIFIC ADVISORY BOARD	BMS/PFE, BAYER, Daiichi-Sankyo

TRIAL ORGANIZATION

EXECUTIVE/STEERING COMMITTEE

Eduardo Ramacciotti | Science Valley Research Institute

Leandro Barile Agati | Science Valley Research Institute

Daniela Calderaro | Heart Institute (InCor) and Clinics Hospital

Alfonso Tafur | Northshore University Health System

Alex C. Spyropoulos | Northwell Institutes for Medical Research

Renato D. Lopes | Brazilian Clinical Research Institute (BCRI)

Duke Clinical Research Institute (DCRI)

Rogério Krakauer (Santa Casa de São Paulo School of Medical Sciences)

Oswaldo De Lima (General Surgery, Leforte Hospital)

STATISTICAL ANALYSIS

Chang Chiann (University of São Paulo)

CLINICAL EVENTS CLASSIFICATION (CEC) COMMITTEE

Science Valley Research Institute

COORDINATING CENTER

Science Valley Research Institute



SPONSOR/ FUNDING

Science Valley Research Institute

COLLABORATION



(*) Unrestricted research grant from Bayer S.A., which was not involved in design, conduct or interpretation of the study

BACKGROUND

1

The devastating Coronavirus disease (COVID-19) pandemic is associated with a high prothrombotic state ¹

2

It is unclear if the coagulation abnormalities occur because of the direct effect of SARS-CoV-2 or indirectly by the cytokine storm and endothelial damage or by a combination of mechanisms ²

3

There is a clear indication of in-hospital pharmacological thromboprophylaxis for every patient with COVID-19 after bleeding risk assessment ³

4

There is no consensus on the role of extended thromboprophylaxis ⁴


5

Current antithrombotic statements are conflicting for the need (or not) for post-hospital discharge thromboprophylaxis in hospitalized COVID-19 patients ⁵

1. Klok et al. Thromb Res 2020;191:145-147; 2. Ackermann et al. N Engl J Med 2020;383(2):120-128; 3. Spyropoulos et al. J Thromb Haemost 2020;18(8):1859-1865; 4. Moores et al. Chest 2020;158(3):1143-1163; 5. Gerotziakas et al. Thromb Haemost 2020;120(12):1597-1628.

↓ **56%** symptomatic VTE
No ↑ Bleeds

Significant Reduction of Symptomatic VTE with Rivaroxaban After Discharge in Acutely Medically Ill Patients



IMPROVE DD VTE

RISK SCORE

VTE RISK FACTOR	POINTS
Previous VTE	3
Known thrombophilia	2
Lower-limb paralysis	2
History of cancer (*)	2
Immobilization ≥ 1 day (*)	1
ICU/CCU stay	1
Age >60 years	1
D dimer $\geq 2X$ UNL	2



with
IM
Dd
rec

Primary
pulmon
events

Power:

(*) Modified for the MARINER clinical trial | ICU = intensive care unit; CCU = critical care unit.

Spyropoulos AC et al Chest 2011; 140:706-14

ary

day 75
one call)

e limb

KEY INCLUSION AND EXCLUSION CRITERIA

KEY INCLUSION CRITERIA

- Patients \geq 18 years hospitalized for minimum of 3 days with standard dose thromboprophylaxis (LMWH, fondaparinux or UFH) prior to randomization for SARS-CoV-2 infection (COVID-19)
- Total modified IMPROVE VTE Risk Score \geq 4 OR total modified IMPROVE VTE Risk Score 2 or 3 and D dimer $>$ 500 ng/ml during index hospitalization

KEY EXCLUSION CRITERIA

- Bleeding Risks
 - Any bleeding within 3 months
 - Surgery, biopsy or trauma 4 weeks prior or planned
 - Active gastroduodenal ulcer
 - Active cancer
- Required anticoagulation after discharge
- Use of dual antiplatelet therapy during the index hospitalization
- Creatinine clearance $<$ 30 ml/min
- Concomitant Medications
 - Combined P-gp and strong CYP3A4 inhibitors
 - Combined P-gp and strong CYP3A4 inducers

CLINICAL OUTCOMES

PRIMARY OUTCOME

Composite of symptomatic VTE, VTE-related death, and VTE detected at bilateral lower limbs venous duplex scan and computed tomography pulmonary angiogram and symptomatic arterial thromboembolism, myocardial infarction (MI), non-hemorrhagic stroke, major adverse limb event (MALE), and cardiovascular (CV) death at day 35

KEY SAFETY OUTCOME

Incidence of major bleeding according to ISTH criteria

SECONDARY OUTCOMES

Symptomatic and fatal VTE

Symptomatic VTE + all cause mortality

Symptomatic VTE, MI, stroke and cardiovascular death


Clinical outcomes were adjudicated by an independent committee in a blinded fashion

STATISTICAL ANALYSIS

SAMPLE SIZE CALCULATIONS

- 1** Power of 80% and $\alpha = 0.05$
- 2** Anticipated occurrence of the primary efficacy endpoint of 15% of patients in the control group and 5% of patients in the treatment group (RRR = 67%)
- 3** If there is a true difference in favor of the proposed treatment of an absolute risk reduction of 10% (15% vs. 5%), then 282 patients were required
- 4** With a drop-out rate of 10%, a total of **320** patients was necessary (160 per arm)
- 5** The primary analysis was performed using the intention-to-treat principle

STUDY FLOW-DIAGRAM




BASELINE CHARACTERISTICS

CHARACTERISTICS	RIVAROXABAN (N=159)	CONTROL (N=159)
Mean age(yr) – mean(SD)	57.8 (14.8)	56.4 (15.6)
Age ≥75 yr – n° (%)	18 (11.3%)	15 (9.4%)
Female sex – n° (%)	62 (39.0%)	65 (40.9%)
BMI – mean(SD)	29.6 (5.6)	29.9 (6.0)
Clearance n./total(%)		
30 to <50 ml/min	6/158 (3.8%)	5/157 (3.2%)
≥50 ml/min	152/158 (96.2%)	152/157 (96.8%)
Mean duration of index hospitalization – days -mean(SD)	16.4 (46.7)	12.6 (28.5)
ICU or CCU stay – n° (%)	86 (54.1%)	79 (49.7%)
In-hospital enoxaparin 40 mg use – n° (%)	136 (85.5%)	137 (86.2%)
In-hospital unfractionated heparin use – n° (%)	23 (14.5%)	22 (13.8%)
IMPROVE score n.(%)		
2-3	98 (61.6%)	99 (62.3%)
≥4	61 (38.4%)	60 (37.7%)
D-Dimer level above the UNL during index hospitalization – n°/total (%)	106/115 (92.2%)	108/118 (91.5%)
Antiplatelets use – n° (%)	8 (5.0%)	8 (5.0%)

PRIMARY EFFICACY/SAFETY OUTCOMES

RR = 0.33 (0.13–0.90)
p=0.03 (superiority)
NNT = 16




*Composite of composite of symptomatic VTE, VTE-related death, asymptomatic VTE (Doppler and AngioCT scan) and symptomatic ATE, MI, non-hemorrhagic stroke, (MALE), and cardiovascular death at day 35.

SECONDARY EFFICACY OUTCOMES

Secondary efficacy outcomes	RIVAROXABAN (N = 159)	CONTROL (N = 159)	RELATIVE RISK (95% CI)
Symptomatic + fatal VTE	1/159 (0.63%)	8/159 (5.03%)	0.13 (0.02 – 0.99)
Symptomatic VTE + all cause mortality	4/159 (2.52%)	9/159 (5.66%)	0.44 (0.14 – 1.41)
A composite of Symptomatic VTE, MI, stroke and cardiovascular deaths	1/159 (0.63%)	9/159 (5.66%)	0.11 (0.01 – 0.87)
Components of the primary outcome			
Symptomatic DVT	0	3 (1.89%)	0.14 (0.01 – 2.74)
Symptomatic PE	1 (0.63%)	2 (1.26%)	0.50 (0.05 – 5.46)
Fatal PE	0	3 (1.89%)	0.14 (0.01 – 2.74)
Asymptomatic DVT detected at duplex scan	3 (1.89%)	1 (0.63%)	3.00 (0.32 – 28.53)
Asymptomatic PE detected at CT pulmonary angiogram	1 (0.63%)	4 (2.52%)	0.25 (0.03– 2.21)
Symptomatic arterial thrombosis	0	1 (0.63%)	0.33 (0.01 – 8.12)
Myocardial infarction	0	0	-
Non-hemorrhagic stroke	0	0	-
Major adverse limb event (MALE)	0	0	-
Cardiovascular deaths	0	1 (0.63%)	0.33 (0.01 – 8.12)












SECONDARY EFFICACY OUTCOMES



SAFETY OUTCOMES

	Rivaroxaban (n=159)	Control (n=159)
Principal safety outcome: major bleeding	0	0
Clinically relevant nonmajor bleeding	2 (1.26%)	2 (1.26%)
Another bleeding	2 (1.26%)	1 (0.63%)
A combination of major and clinically relevant non-major bleeding and other bleeding	4 (2.51%)	3 (1.89%)

SUBGROUP ANALYSIS

SUBGROUP		RIVAROXABAN n./total(%)	CONTROL n./total(%)		RR (IC 95%)
Age (yrs)	≤60	2/77 (2.60%)	4/92 (4.35%)		0.60 (0.11 – 3.17)
	>60	3/82 (3.66%)	11/67 (16.42%)		0.22 (0.07 – 0.77)
BMI	≤30	3/105 (2.86%)	10/88 (11.36%)		0.25 (0.07 – 0.89)
	>30	2/54 (3.70%)	5/71 (7.04%)		0.53 (0.11 – 2.61)
Creatinine Clearance ml/min	30 to <50 ml/min	0/6	0/5		---
	≥50 ml/min	5/152 (3.29%)	15/154 (9.74%)		0.34 (0.13 – 0.91)
Modified IMPROVE VTE risk score	2-3	2/98 (2.04%)	9/99 (9.09%)		0.22 (0.05 – 1.01)
	≥4	3/61 (4.92%)	6/60 (10.0%)		0.49 (0.13 – 1.88)
D-Dimer level above the UNL	≤500 ng/ml	0/9 (0.00%)	1/10 (10.00%)		0.37 (0.02 – 7.99)
	>500 ng/ml	4/106 (3.77%)	10/108 (9.26%)		0.41 (0.13 – 1.26)
Antiplatelets use — no. (%)	no	5/151 (3.31%)	14/151 (9.27%)		0.36 (0.13 – 0.97)
	yes	0/8 (0.00%)	1/8 (12.5%)		0.33 (0.02 – 7.02)

Favors rivaroxaban 1 Favors control

CONCLUSION

In patients discharged after hospitalization due to COVID-19 with increased IMPROVE score, thromboprophylaxis with rivaroxaban 10 mg once-daily for 35 days **improved clinical outcomes, without increasing bleeding** compared with no out-of-hospital anticoagulation

ACKNOWLEDGMENTS

Science Valley Research Institute, Bayer Brazil team, investigators, hospitals, study coordinators, DSMB, CEC, core-lab, and study participants who made the MICHELLE trial possible.



THANK YOU